Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.34Last Year’s EPS
-0.3Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a largely positive operational and commercial story: strong 2025 revenue growth (55% YoY), improved commercial margins (~55%), a healthy cash position and successful financing, multiple regulatory approvals, and an expanded pipeline with several near-term potentially registrational readouts. Key risks include a planned material increase in R&D spend (approximately $150M tied to brolobitug) compressing expenses into 2026, a deceleration in revenue growth implied by 2026 guidance (~21%–25% vs 55% in 2025), some region-specific revenue headwinds (Japan), and clinical/regulatory and competitive uncertainties for upcoming programs. Overall, the company appears well funded and operationally strong but will face elevated near-term spend and execution risk around trial readouts and regulatory interactions.Company Guidance
Strong Top-Line Revenue Growth
Total net product sales of $521 million in FY2025 vs $330 million in FY2024, representing 55% year-over-year growth; Q4 2025 net product sales of $149 million vs $99 million in Q4 2024 (~+50.5%).
Product Sales Mix and Strength of Livmarli
Livmarli net product sales of $245 million in the U.S. and $115 million internationally (total Livmarli $360 million), with the bile acid medicines contributing $161 million, combining to the $521 million FY2025 total.
Confident 2026 Revenue Guidance
Company expects FY2026 net product sales of $630 million to $650 million, implying ~21%–25% growth versus FY2025 (management noted ramp and confidence entering 2026).
Improved Commercial Profitability
Commercial cash contribution margin was approximately 55% in 2025, described as a significant increase from the prior year.
Stronger Balance Sheet and Financing Completed
Cash, cash equivalents and investments of $391 million at 12/31/2025, up from $293 million at 12/31/2024 (+$98 million, ~+33.4%); completed two private placements concurrent with the Bluejay acquisition raising aggregate gross proceeds of $268.5 million, and reported positive cash flow from operations in 2025.
Pipeline and Regulatory Progress
Key regulatory/clinical milestones in 2025 included approval of Cholbam for CTX, approval of a tablet formulation of Livmarli, completion of enrollment in the VISTA study (volixibat in PSC), and Fast Track designation for MRN-3,379 in Fragile X syndrome.
Strategic Portfolio Expansion and Near-Term Catalysts
Acquisition/added Phase III brolobitug program for chronic hepatitis delta; company now expects four potentially registrational readouts over the next ~18 months (VISTA top-line and AZURE-1 interim in Q2; AZURE-1 and AZURE-4 top-line in H2; EXPAND top-line in Q4; VANTAGE in H1 next year), creating operating leverage and multiple near-term value catalysts.
Operational Execution and Integration
Management reported disciplined execution in 2025, smooth integration of the recent transaction (Bluejay), and enrollment across clinical programs is on track or ahead of timelines.
MIRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MIRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | $108.62 | $92.19 | -15.13% |
Nov 04, 2025 | $70.97 | $70.09 | -1.24% |
Aug 06, 2025 | $53.39 | $59.82 | +12.04% |
May 07, 2025 | $41.22 | $45.24 | +9.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mirum Pharmaceuticals Inc (MIRM) report earnings?
Mirum Pharmaceuticals Inc (MIRM) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Mirum Pharmaceuticals Inc (MIRM) earnings time?
Mirum Pharmaceuticals Inc (MIRM) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MIRM EPS forecast?
MIRM EPS forecast for the fiscal quarter 2026 (Q1) is -0.34.